Citius Oncology Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
1analyst covering
FY EPS (est.)
-$0.60next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Nasdaq Minimum Bid Price Compliance Deadline | 19 Oct 2026 |
| FY 2026 Annual Report (Form 10-K) | 23 Dec 2026 |
Monitoring Framework
Key Performance Indicators
LYMPHIR Net Product Revenue Quarterly5.6M
LYMPHIR Gross Profit Margin Quarterly80.0%
Formulary Inclusion Rate among Target Accounts Quarterly83.0%Target: 90+%
Watch Items
- Nasdaq Minimum Bid Price ComplianceTrigger: Stock price below $1.00 for 30 consecutive business daysAction: Regain compliance by October 19, 2026, or implement a reverse stock split to maintain Nasdaq Capital Market listing.
- Avenue Capital Credit Facility Milestone TranchesTrigger: Achievement of predefined revenue and liquidity milestonesAction: Unlock the remaining $15 million in two tranches ($7 million starting Oct 1, 2026, and $8 million starting Jan 1, 2027) to extend cash runway.
- LYMPHIR Clinical Expansion (Combination Trials)Trigger: Topline data readouts from investigator-initiated Phase 1 trialsAction: Evaluate combination efficacy with pembrolizumab in solid tumors and CAR-T pre-dosing in DLBCL to expand addressable market.
Research as of 19 Jun 2026